[go: up one dir, main page]

AR123805A1 - Cápsulas blandas de liberación modificada - Google Patents

Cápsulas blandas de liberación modificada

Info

Publication number
AR123805A1
AR123805A1 ARP210102856A ARP210102856A AR123805A1 AR 123805 A1 AR123805 A1 AR 123805A1 AR P210102856 A ARP210102856 A AR P210102856A AR P210102856 A ARP210102856 A AR P210102856A AR 123805 A1 AR123805 A1 AR 123805A1
Authority
AR
Argentina
Prior art keywords
dependent
controlled release
modified release
tract
active agent
Prior art date
Application number
ARP210102856A
Other languages
English (en)
Inventor
Qi Fang
Karunakar Sukuru
Original Assignee
Scherer Technologies Llc R P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherer Technologies Llc R P filed Critical Scherer Technologies Llc R P
Publication of AR123805A1 publication Critical patent/AR123805A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen cápsulas blandas de liberación modificada que incluyen una composición de cubierta dependiente del pH que encapsula una composición de relleno de liberación controlada, los métodos de preparación correspondientes y métodos de uso de estas. La composición de la cubierta dependiente del pH puede estar caracterizada por la naturaleza de liberación retardada de las cápsulas que puede lograrse sin un recubrimiento separado dependiente del pH o sin añadir polímeros convencionales dependientes del pH. Las cápsulas blandas proporcionan una plataforma de liberación controlada dual que facilita el suministro del agente activo en un lugar objetivo en el tubo digestivo y un perfil de liberación controlada del agente activo en dicho lugar objetivo en el tubo digestivo.
ARP210102856A 2020-10-16 2021-10-15 Cápsulas blandas de liberación modificada AR123805A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063092762P 2020-10-16 2020-10-16

Publications (1)

Publication Number Publication Date
AR123805A1 true AR123805A1 (es) 2023-01-11

Family

ID=81208677

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102856A AR123805A1 (es) 2020-10-16 2021-10-15 Cápsulas blandas de liberación modificada

Country Status (14)

Country Link
US (1) US20230390210A1 (es)
EP (1) EP4228597A4 (es)
JP (1) JP2023547062A (es)
KR (1) KR20230088388A (es)
CN (1) CN116322655A (es)
AR (1) AR123805A1 (es)
AU (1) AU2021362248A1 (es)
BR (1) BR112023006154A2 (es)
CA (1) CA3194160A1 (es)
CO (1) CO2023005753A2 (es)
IL (1) IL301715A (es)
MX (1) MX2023004418A (es)
TW (1) TW202228656A (es)
WO (1) WO2022082222A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025135085A1 (ja) * 2023-12-22 2025-06-26 花王株式会社 カプセル剤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708834A (en) * 1986-05-01 1987-11-24 Pharmacaps, Inc. Preparation of gelatin-encapsulated controlled release composition
US7842307B2 (en) * 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US7255921B2 (en) * 2001-11-22 2007-08-14 Morishita Jintan Co., Ltd. Non-gelatinous capsule shell composition and a capsule formed from the same
KR100575199B1 (ko) * 2003-01-24 2006-05-02 알앤피코리아주식회사 연질 캡슐의 블루밍 방지를 위한 가소제 조성물 및 이를함유한 피막
IT1401313B1 (it) * 2010-08-05 2013-07-18 Perfetti Van Melle Spa Caramelle gelatinose con ripieno fluido e metodo di ottenimento
US20120301546A1 (en) * 2011-05-26 2012-11-29 Hassan Emadeldin M Acid-resistant soft gel compositions
GB201304662D0 (en) * 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
GB201319792D0 (en) * 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
WO2015200149A1 (en) * 2014-06-23 2015-12-30 Banner Life Sciences Llc All natural enteric soft capsules comprising active ingredients
US20170119680A1 (en) * 2015-10-30 2017-05-04 R.P. Scherer Technologies, Llc Extended release film-coated capsules
WO2020081649A1 (en) * 2018-10-16 2020-04-23 Bayer Healthcare Llc Softgels with solid or gel-like polymeric fill matrix
EP4674410A2 (en) * 2019-10-28 2026-01-07 R.P. Scherer Technologies, LLC Delayed release softgel capsules in higher ph environment

Also Published As

Publication number Publication date
TW202228656A (zh) 2022-08-01
KR20230088388A (ko) 2023-06-19
CA3194160A1 (en) 2022-04-21
AU2021362248A9 (en) 2024-05-02
EP4228597A4 (en) 2024-10-02
US20230390210A1 (en) 2023-12-07
CN116322655A (zh) 2023-06-23
IL301715A (en) 2023-05-01
EP4228597A1 (en) 2023-08-23
BR112023006154A2 (pt) 2023-05-09
CO2023005753A2 (es) 2023-05-29
JP2023547062A (ja) 2023-11-09
MX2023004418A (es) 2023-05-04
AU2021362248A1 (en) 2023-06-01
WO2022082222A1 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
PE20180931A1 (es) Metodo de cristalizacion y biodisponibilidad
CY1121587T1 (el) Καψα χορηγησης
CO6290641A2 (es) Preparacion de capsula que contiene los ingredientes farmaceuticamente activos liquidos y solidos, la cual presenta exelentes propiedades de los ingredientes farmaceuticamente activos
CO2023007156A2 (es) Cápsulas de gel blando de liberación retardada
MX387217B (es) Composiciones de solución sólida para aines.
CY1117964T1 (el) Αντιψυχωτικη ενεσιμη συνθεση μακρας διαρκειας δρασης τεχνικος τομεας
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
AR120057A1 (es) Composiciones neoantigénicas y usos de estas
CR20170142A (es) Composiciones farmacéuticas resistentes al abuso
AR123805A1 (es) Cápsulas blandas de liberación modificada
CL2021003286A1 (es) Cápsula de tipo desintegración retardada y método para producir la misma.
MX2019005627A (es) Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerotica.
PH12015000297A1 (en) Pharmaceutical combination preparation
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
BR112015022946A2 (pt) forma de dosagem de cápsula de gelatina macia farmacêutica com goma guar modificada
CO2022019321A2 (es) Cápsulas de gel de liberación retardada
MX2018001989A (es) Formulaciones farmaceuticas.
EA201071138A1 (ru) Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона
SV2006001916A (es) Formulaciones farmaceuticas transdermales
MX2021011795A (es) Composición farmaceutica que comprende esomeprazol 0 sal farmaceuticamente aceptable del mismo y que tiene un perfil de liberación doble.
MX2012010707A (es) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos.
EA201491995A1 (ru) Пероральная лекарственная форма
PE20200017A1 (es) Composiciones de insulina de rapida accion
PE20171340A1 (es) Composicion farmaceutica para el tratamiento de enfermedades gastrointestinales
CL2019001555A1 (es) Preparación farmacéutica y método para su fabricación.